The Importance of Diversity in Breast Cancer Clinical Trials September 15, 2021 Dr. Lola Fayanju is the Helen O. Dickens Presidential Associate Professor at the Perelman School of Medicine at the University of Pennsylvania, where she is also chief of breast surgery at Penn Medicine, as well as surgical director of the Rena…
“Enhertu slashed the risk of disease progression or death by a massive 71.6% over Kadcyla in second-line HER2-positive metastatic breast cancer patients previously treated with Roche's Herceptin and chemo, AstraZeneca and Daiichi reported at the European Society for Medical Oncology 2021 virtual meeting. “The showing is so…
Improved Survival With Surgery in Metastatic Breast Cancer | MedPage Today "Selected patients with metastatic breast cancer at diagnosis had significantly better survival with surgery in addition to systemic therapy, an analysis of almost 13,000 patients showed." "Primary Source Annals of Surgical Oncology Source…